[go: up one dir, main page]

HRP20000468A2 - Hypolipidemic benzothiazepine compounds - Google Patents

Hypolipidemic benzothiazepine compounds Download PDF

Info

Publication number
HRP20000468A2
HRP20000468A2 HR20000468A HRP20000468A HRP20000468A2 HR P20000468 A2 HRP20000468 A2 HR P20000468A2 HR 20000468 A HR20000468 A HR 20000468A HR P20000468 A HRP20000468 A HR P20000468A HR P20000468 A2 HRP20000468 A2 HR P20000468A2
Authority
HR
Croatia
Prior art keywords
compound
formula
functional derivative
physiologically functional
solute
Prior art date
Application number
HR20000468A
Other languages
English (en)
Croatian (hr)
Inventor
Anthony Louis Handlon
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of HRP20000468A2 publication Critical patent/HRP20000468A2/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D281/00Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02Seven-membered rings
    • C07D281/04Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/10Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
HR20000468A 1998-01-10 1999-01-07 Hypolipidemic benzothiazepine compounds HRP20000468A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9800428.6A GB9800428D0 (en) 1998-01-10 1998-01-10 Chemical compounds
PCT/EP1999/000021 WO1999035135A1 (en) 1998-01-10 1999-01-07 Hypolipidemic benzothiazepine compounds

Publications (1)

Publication Number Publication Date
HRP20000468A2 true HRP20000468A2 (en) 2000-10-31

Family

ID=10825042

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20000468A HRP20000468A2 (en) 1998-01-10 1999-01-07 Hypolipidemic benzothiazepine compounds

Country Status (27)

Country Link
US (1) US6465451B1 (is)
EP (1) EP1045840A1 (is)
JP (1) JP2002500220A (is)
KR (1) KR20010033988A (is)
CN (1) CN1292785A (is)
AP (1) AP2000001860A0 (is)
AR (1) AR014261A1 (is)
AU (1) AU2515599A (is)
BR (1) BR9906799A (is)
CA (1) CA2317651A1 (is)
CO (1) CO4820391A1 (is)
EA (1) EA200000623A1 (is)
GB (1) GB9800428D0 (is)
HR (1) HRP20000468A2 (is)
HU (1) HUP0201343A3 (is)
ID (1) ID25495A (is)
IL (1) IL137040A0 (is)
IS (1) IS5551A (is)
MA (1) MA26595A1 (is)
NO (1) NO20003514L (is)
NZ (1) NZ505453A (is)
PE (1) PE20000179A1 (is)
PL (1) PL341672A1 (is)
SK (1) SK10242000A3 (is)
TR (1) TR200001816T2 (is)
WO (1) WO1999035135A1 (is)
ZA (1) ZA9981B (is)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
KR20010102964A (ko) * 1998-12-23 2001-11-17 윌리암스 로저 에이 심장혈관 징후를 위한 회장 담즙산 수송 억제인자 및피브린산 유도체의 조합물
DE69908643T2 (de) 1998-12-23 2004-05-13 G.D. Searle Llc, Chicago Kombinationen von cholesteryl ester transfer protein inhibitoren und nicotinsäure derivaten für kardiovaskuläre indikationen
SE0000772D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab Chemical compounds
US20020061888A1 (en) * 2000-03-10 2002-05-23 Keller Bradley T. Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
US20020183307A1 (en) * 2000-07-26 2002-12-05 Tremont Samuel J. Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake
SE0003766D0 (sv) * 2000-10-18 2000-10-18 Astrazeneca Ab Novel formulation
EG26979A (en) * 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
GB0121337D0 (en) * 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) * 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
MY131995A (en) 2001-09-08 2007-09-28 Astrazeneca Ab Benzothiazepine and benzothiadiazepine derivatives with illeal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia
JP2005521653A (ja) 2002-01-17 2005-07-21 ファルマシア コーポレイション 先端ナトリウム同時依存性胆汁酸輸送(asbt)およびタウロコール酸塩取込みの阻害剤としての新規アルキル/アリールヒドロキシまたはケトチエピン化合物
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
FR2849024B1 (fr) * 2002-12-20 2007-11-02 Aventis Pharma Sa Nouveaux composes chiraux derives d'esters de l'acide hexanoique, procede et intermediaires de preparation, utilisation a la synthese de l'acide 2-(bromomethyl)2-ethyl hexanoique chiral
GB0304194D0 (en) 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
CN102316872B (zh) 2008-11-26 2016-12-21 萨蒂奥根制药公司 治疗肥胖症和糖尿病的胆汁酸再循环抑制剂
EP4137137A1 (en) 2010-05-26 2023-02-22 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
CA2815749C (en) 2010-11-04 2019-12-03 Albireo Ab Ibat inhibitors for the treatment of liver diseases
SG190433A1 (en) 2010-11-08 2013-06-28 Albireo Ab A pharmaceutical combination comprising an ibat inhibitor and a bile acid binder
EP2770990A4 (en) 2011-10-28 2015-03-11 Lumena Pharmaceuticals Inc Gallic acid refluxing agent for the treatment of hypertension and chronic liver disease
PT2771003T (pt) 2011-10-28 2017-07-26 Lumena Pharmaceuticals Llc Inibidores da reciclagem de ácidos biliares para tratamento de doenças hepáticas colestáticas pediátricas
AU2014228850A1 (en) 2013-03-15 2015-10-29 Lumena Pharmaceuticals Llc Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
MX2015013196A (es) 2013-03-15 2016-04-15 Lumena Pharmaceuticals Inc Inhibidores de reciclaje de acidos biliares para el tratamiento de la enfermedad de reflujo gastroesofagico y esofago de barrett.
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
JP6751020B2 (ja) 2014-06-25 2020-09-02 Eaファーマ株式会社 固形製剤及びその着色防止又は着色低減方法
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
EP3413878B1 (en) 2016-02-09 2021-04-14 Albireo AB Oral cholestyramine formulation and use thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
JP6954926B2 (ja) 2016-02-09 2021-10-27 アルビレオ・アクチボラグ 経口コレスチラミン製剤及びその使用
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
CA3071285A1 (en) 2017-08-09 2019-02-14 Albireo Ab Cholestyramine granules, oral cholestyramine formulations and use thereof
WO2019032027A1 (en) 2017-08-09 2019-02-14 Albireo Ab CHOLESTYRAMINE TABLETS, ORAL FORMULATIONS OF CHOLESTYRAMINE AND THEIR USE
TW202015699A (zh) 2018-06-05 2020-05-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽汁酸調節劑之用途
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
WO2019245448A1 (en) 2018-06-20 2019-12-26 Albireo Ab Crystal modifications of odevixibat
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
MX2021008981A (es) 2019-02-06 2021-09-08 Albireo Ab Compuestos de benzotiadiazepina y su uso como moduladores del acido biliar.
CN118834175A (zh) 2019-02-06 2024-10-25 阿尔比里奥公司 苯并硫氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
WO2020167964A1 (en) 2019-02-12 2020-08-20 Mirum Pharmaceuticals, Inc. Genotype and dose-dependent response to an asbti in patients with bile salt export pump deficiency
AR120676A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzoti(di)azepina y su uso como ácido biliar
TWI877263B (zh) 2019-12-04 2025-03-21 瑞典商艾爾比瑞歐公司 苯并噻二氮呯化合物及其作為膽酸調節劑之用途
CN114761080B (zh) * 2019-12-04 2024-07-23 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
CA3158175A1 (en) * 2019-12-04 2021-06-10 Per-Goran Gillberg Benzothiazepine compounds and their use as bile acid modulators
CN114761018B (zh) 2019-12-04 2025-12-02 阿尔比里奥公司 苯并硫杂二氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
CN114786772B (zh) * 2019-12-04 2024-04-09 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
AR120679A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzoti(di)azepina y su uso como moduladores ácido biliar
BR112022010505A2 (pt) 2019-12-04 2022-09-06 Albireo Ab Compostos de benzotia(di)azepina e seu uso como moduladores do ácido biliar
WO2021110884A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
WO2021110887A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
CA3186857A1 (en) 2020-08-03 2022-02-10 Per-Goran Gillberg Benzothia(di)azepine compounds and their use as bile acid modulators
JP2023549226A (ja) 2020-11-12 2023-11-22 アルビレオ エービー 進行性家族性肝内胆汁うっ滞症(pfic)を処置するためのオデビキシバット
WO2022117778A1 (en) * 2020-12-04 2022-06-09 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
CN119343140A (zh) 2022-06-09 2025-01-21 阿尔比里奥公司 治疗肝炎
WO2025146508A1 (en) 2024-01-05 2025-07-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
WO2025146507A1 (en) 2024-01-05 2025-07-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0723449A1 (en) 1993-08-06 1996-07-31 Smithkline Beecham Corporation Endothelin receptor antagonists
ZA956647B (en) 1994-08-10 1997-02-10 Wellcome Found Hypolipidaemic compounds.
GB9423172D0 (en) * 1994-11-17 1995-01-04 Wellcom Foundation The Limited Hypolipidemic benzothiazepines

Also Published As

Publication number Publication date
EP1045840A1 (en) 2000-10-25
SK10242000A3 (sk) 2001-02-12
EA200000623A1 (ru) 2001-04-23
PE20000179A1 (es) 2000-03-16
NO20003514L (no) 2000-09-07
HUP0201343A2 (hu) 2003-06-28
PL341672A1 (en) 2001-04-23
NO20003514D0 (no) 2000-07-07
HUP0201343A3 (en) 2003-08-28
US6465451B1 (en) 2002-10-15
GB9800428D0 (en) 1998-03-04
CA2317651A1 (en) 1999-07-15
CN1292785A (zh) 2001-04-25
WO1999035135A1 (en) 1999-07-15
CO4820391A1 (es) 1999-07-28
AR014261A1 (es) 2001-02-07
IL137040A0 (en) 2001-06-14
ID25495A (id) 2000-10-05
KR20010033988A (ko) 2001-04-25
NZ505453A (en) 2002-11-26
AU2515599A (en) 1999-07-26
AP2000001860A0 (en) 2000-09-30
BR9906799A (pt) 2000-10-10
TR200001816T2 (tr) 2000-11-21
IS5551A (is) 2000-06-27
JP2002500220A (ja) 2002-01-08
MA26595A1 (fr) 2004-12-20
ZA9981B (en) 2000-07-06

Similar Documents

Publication Publication Date Title
HRP20000468A2 (en) Hypolipidemic benzothiazepine compounds
DE69528704T2 (de) Lipidsenkende 1,4-benzothiazepin-1,1-dioxide
JPH11500102A (ja) 低脂血症性ベンゾチアゼピン
JPS59128359A (ja) バルブロイツクアシツドの1′−エトキシカルボニルオキシエチルエステル、その製造方法、およびそのエステルを含有する抗てんかん用薬剤
CN1812968B (zh) 4-[6-乙酰基-3-[3-(4-乙酰基-3-羟基-2-丙基苯硫基)丙基]-2-丙基苯氧基]丁酸的多晶型物
EP3613742B1 (en) Indolizine derivatives and application thereof in medicine
EP3854781B1 (en) Dp antagonists
JPS61112077A (ja) 8−置換されたヌクレオシド及びプリン誘導体
EP0350878B1 (en) Conjugated gamma-oxybutenolide compounds for treating ulcer
GB2038818A (en) ???,???-Dihydropolyprenyl Alcohols and Pharmaceutical Compositions thereof
EP0030632B1 (de) Benzothiazolderivate, diese enthaltende pharmazeutische Zubereitungen und Verfahren zu ihrer Herstellung
CA2744458A1 (en) Novel processes and pure polymorphs
DE2812353A1 (de) Oxazol- und thiazol-alkansaeureverbindungen, verfahren zu ihrer herstellung und sie enthaltendes pharmazeutisches mittel
EP0240233A1 (en) Derivatives of benzoquinonyl-phenyl alkanoic acid amide
CZ20002556A3 (cs) Hypolipidemické benzothiazepinové sloučeniny
MXPA00006639A (en) Hypolipidemic benzothiazepine compounds
EP0040433B1 (en) Nicotinic derivatives of glucosamine, process for their preparation and related pharmaceutical compositions
JPH05105627A (ja) 腸機能性疾患の治療に用いられる新規な医薬組成物と、その調整方法と、治療用医薬の調製方法
US20060241163A1 (en) Optically active (S)-hydantoin derivative
EP0147174B1 (en) Dihydroxybenzaldehyde derivatives as anti-inflammatory agents
WO2010061219A2 (en) Polymorphs
WO2009091732A1 (en) Compounds for the treatment of metabolic disorders
EP0240338A1 (en) Butenoic acid derivatives
WO2024059331A1 (en) Erythritol ester of phenyl butyric acid
JPS6115A (ja) リポキシゲナ−ゼ代謝産物に起因する疾患の予防治療剤

Legal Events

Date Code Title Description
A1OB Publication of a patent application
OBST Application withdrawn